Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06514794 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
A Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia, sponsored by Wugen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 125
- Enrollment target
- 10
- Study locations
NCT06514794 is a Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia that is actively recruiting participants, run by Wugen. The registered enrollment target is 125 participants, below the 186-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (33% lower). The trial reports 10 study locations across 8 states.
The verdict
NCT06514794, a Phase 2 study of Lymphoblastic Lymphoma and T-cell Acute Lymphoblastic Leukemia, is actively recruiting participants, sponsored by Wugen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 125 participants
- Enrollment target
- 10
- Study locations
Study Summary
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Conditions Studied
Interventions
- BIOLOGICAL WU-CART-007
Study Locations (10)
California
- City of Hope - Duarte
- Children's Hospital Los Angeles - Los Angeles
Victoria
- Peter Mac Callum Cancer Institute - Melbourne
- Royal Children's Melbourne - Melbourne
Florida
- H. Lee Moffitt Cancer Center and Research Institute Hospital - Tampa
Missouri
- Washington University Saint Louis - St Louis
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
Texas
- MD Anderson Cancer Center - Houston
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 125 participants |
| Start Date | 2025-01-31 |
| Est. Completion | 2028-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06514794
The ClinicalTrials.gov registry entry for NCT06514794 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 186-participant average among 21 other Lymphoblastic Lymphoma trials with a reported enrollment target (33% lower). The listed sponsor is Wugen, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Lymphoblastic Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which WU-CART-007 is the first listed.
NCT06514794 reports 10 study locations spanning 8 distinct geographic areas - top geographies include California, Victoria, Florida.
Frequently Asked Questions
What is clinical trial NCT06514794 about?
NCT06514794 is a clinical study titled "A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)". The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
What is the current status of trial NCT06514794?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 125 participants. The study started on 2025-01-31. Estimated completion is 2028-12-30.
What conditions does trial NCT06514794 study?
This clinical trial studies the following conditions: Lymphoblastic Lymphoma, T-cell Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT06514794?
The interventions under investigation include: WU-CART-007 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06514794?
This trial is sponsored by Wugen, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06514794 being conducted?
This trial has 10 study locations across California, Florida, Missouri, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoblastic Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
RECRUITING · Phase 2
-
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RECRUITING · Phase 2
-
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
RECRUITING · Phase 2
-
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
RECRUITING · Phase 2
-
Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
-
SC-PEG Asparaginase vs. Oncaspar in Pediatric Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Lymphoblastic Lymphoma
All registered trials for this condition
T-cell Acute Lymphoblastic Leukemia
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.